Replies to post #193873 on Biotech Values

[biomaven0]

(OT)

>>Slo Niacin

Bad idea in my view. Aside from potential liver issues with high-dose OTC niacin, Merck's large niacin trial (25k patients over 4 years) showed reduced LDL, increased HDL (sounds good, right?) but no decrease in cardiac events at all and marked adverse effects including increased diabetes. Some of the AE's could have come from the other ingredient designed to stop flushing, but likely the diabetes at least related to the niacin.

Other niacin trials have similarly not shown any actual improvements except for improved HDL, which is likely just a red herring here.

Peter